Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Nanobiotix    NANO   FR0011341205

NANOBIOTIX (NANO)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
09/18/2018 09/19/2018 09/20/2018 09/21/2018 09/24/2018 Date
17.49(c) 17.43(c) 16.92(c) 16.6(c) 16.28 Last
156 493 85 499 286 160 153 655 76 655 Volume
+0.69% -0.34% -2.93% -1.89% -1.93% Change
More quotes
Financials (EUR)
Sales 2018 7,28 M
EBIT 2018 -25,4 M
Net income 2018 -24,7 M
Finance 2018 12,4 M
Yield 2018 -
Sales 2019 11,0 M
EBIT 2019 -28,2 M
Net income 2019 -27,7 M
Finance 2019 5,03 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 43,1x
EV / Sales2019 29,2x
Capitalization 326 M
More Financials
Company
Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer.The company's technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells.It also engages in the development of magnetic particles and laser activated... 
More about the company
Surperformance© ratings of Nanobiotix
Trading Rating : Investor Rating :
More Ratings
Latest news on NANOBIOTIX
09/22NANOBIOTIX : Update on Head and Neck Phase I/II Trial with NBTXR3 and Other prog..
AQ
09/20SCIENTIFIC CLINICAL | NANOBIOTIX : Update on Head and Neck Phase I/II Trial with..
PU
09/20NANOBIOTIX : Update on Head and Neck Phase I/II Trial with NBTXR3 and Other prog..
GL
09/05NANOBIOTIX : Half-year results
CO
09/04NANOBIOTIX : Financial | Nanobiotix half year results for the six months ended J..
PU
09/04NANOBIOTIX : half year results for the six months ended June 30, 2018
AQ
09/04NANOBIOTIX : Half-year results
CO
08/30NANOBIOTIX SA : half-yearly earnings release
07/28NANOBIOTIX : European support for nanoparticle-based cancer treatment research
AQ
07/28NANOBIOTIX : EIB lends EUR 40 million for research, development and innovation o..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
09/23Investor Events this week: 25-26/09 Oppenheimer Fall Summit w/ $COX $KDS 26/..
4
09/05NANOBIOTIX half year results for the six months ended June 30, 2018  
09/02?Financials this week: 04/09 Nanobiotix $NANO Half Year Results 06/09 Biocar.. 
08/31Nanobiotix $NANO NBTXR3/PEP503 phase 1/2 readout in HNSCC pushed by 2y by Pha.. 
08/12Financials this week: 14/08 Curetis $CURE Half Year Results Investor Events:..
1
More tweets
Qtime:25
News from SeekingAlpha
2015NANOMETRICS : Well-Positioned In A Promising Industry 
2015Nanometrics' (NANO) CEO Timothy Stultz on Q4 2014 Results - Earnings Call Tra.. 
2015Nanometrics Incorporated (NANO) Q4 2014 Results - Earnings Call Webcast 
2015Nanometrics beats by $0.03, beats on revenue 
2015Notable earnings after Monday?s close 
Chart NANOBIOTIX
Duration : Period :
Nanobiotix Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NANOBIOTIX
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 30,0 €
Spread / Average Target 81%
EPS Revisions
Managers
NameTitle
Laurent Lévy Chief Executive Officer
Laurent Condomine Chairman-Supervisory Board
Alain Dostie Chief Operating Officer
Philippe Mauberna Chief Financial Officer
Elsa Borghi Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
NANOBIOTIX11.94%390
CELLTRION, INC.--.--%33 388
IQVIA HOLDINGS INC30.32%25 763
LONZA GROUP18.80%24 291
INCYTE CORPORATION-29.69%14 156
SEATTLE GENETICS, INC.45.35%12 348